| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H14O4 |
| Molecular Weight | 270.28 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)OC
InChI
InChIKey=BKRIRZXWWALTPU-UHFFFAOYSA-N
InChI=1S/C16H14O4/c1-19-15(17)13-7-3-11(4-8-13)12-5-9-14(10-6-12)16(18)20-2/h3-10H,1-2H3
| Molecular Formula | C16H14O4 |
| Molecular Weight | 270.28 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
BIPHENYL DIMETHYL DICARBOXYLATE (BDD) under the brand name Nissel is used in the South Corea for the treatment of chronic hepatitis followed by an increase in serum alanine aminotransferase levels continuously. This compound also participated in clinical trials phase III in the patients with chronic liver disease. In addition, the drug was studied in phase III clinical trials after laparoscopic cholecystectomy. The use of BDD in patients with cholecystitis was expected to inhibit elevated liver enzyme levels and to maintain liver function.